he genomics pioneer who sequenced the human genome carved out a new niche just over a year ago, selling exhaustive $25,000 medical workups to apparently healthy people. Now Craig Venter’s trying to take one small piece of that business to a much wider audience — and to prove it’s worthwhile.

An early step in that direction came this month, when Venter’s company Human Longevity struck a deal with a life insurer to boost its $2,500 whole genome analysis product. For a discounted $1,400, customers and employees of the life insurer, MassMutual, can get every inch of their DNA scoured and then interpreted for what it means for their disease risk. It’s a way to “turn risks into opportunities to outsmart the diseases that may lie in your future,” Human Longevity’s website says of the product.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I am curious: does their report include MTHFR variants and other genes impacting methylation and detoxification pathways?

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.